How much does Adagrasib cost per month? Interpretation of treatment costs and medical insurance policies

Adagrasib: As a new targeted treatment for non-small cell lung cancer (NSCLC), the cost of treatment is an important consideration for patients. The cost of treatment with adagrasib is relatively high, especially since the price of the original drug is relatively expensive globally. The market price of the original version of adagrasib in the United States is approximately 200 mg × 180 tablets per bottle, and the price is usually around hundreds of thousands of yuan, which makes it a major burden for patients during treatment.

Adagrasiib is administered orally at 600 mg twice daily until disease progression or unacceptable toxicity. This means that in the U.S. market, patients’ monthly drug costs are usually tens of thousands of yuan. For patients who require long-term treatment, the cost of drugs will be very huge.

However, as drugs enter the market in other countries, especially generic versions, more economical treatment options become available to patients. For example, the Laos version of the generic version of adagrasibu has a specification of 200 mg × 90 tablets per box and costs about more than 3,000 yuan, which is much cheaper than the original drug. Although the price is significantly lower, the pharmaceutical ingredients of generic drugs are the same as those of the original drugs, so their therapeutic effects and safety can be guaranteed.

It is worth noting that since adagrasib has not yet been officially launched in China, domestic patients usually obtain the drug through overseas purchase channels. This not only affects the accessibility of drugs, but also causes price changes to occur more frequently. For some patients, the cost of this drug may become a financial burden of long-term treatment.

For lung cancer patients who require long-term treatment, medical insurance policy coverage is also crucial. At present, adagrasib is not fully covered by medical insurance policies in some countries, so patients need to bear most of the treatment costs themselves.

References：https://www.krazati.com/